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Abstract
ENGINEERING B CELLS FOR USE IN IMMUNOTHERAPY AND CANCER
Emily Louise Ensley, B.S.
Advisory professor: Katayoun Rezvani, M.D., Ph.D.

B cells can be divided into effector and regulatory immune cells. While effector B cells are
key drivers of humoral immunity due to their ability to generate antibodies specific to
pathogens, regulatory B cells (Bregs) have recently been shown to control inflammatory
responses in multiple diseases through the production of anti-inflammatory cytokines,
including interleukin (IL)-10, IL-35 and transforming growth factor-beta (TGF-b). Ex vivo
expansion of B cells has been challenging due to their tendency to undergo apoptosis in
culture. Thus, creating a successful expansion protocol with exceptional viability will open
the door for B cells to be used directly for adoptive therapy or as a source of antibody
production ex vivo. Furthermore, a strategy to preferentially expand Bregs may be an
attractive approach to mitigate autoimmune disorders and graft-versus-host disease. The
primary goal of this thesis project is to understand factors that skew B cell function and to
develop a protocol for the expansion of Bregs with immunomodulatory properties for cell
therapy. We hypothesized that using genetic engineering tools we can skew the function
of B cells toward a suppressive phenotype and support their ex vivo proliferation and
survival to generate a viable subset of Bregs for cell therapy. We successfully generated
B cells that displayed suppressive capabilities and used mass cytometry to characterize
their phenotype. However, the immunoregulatory function of B cells was transient.
Interrogation of the expanded B cells at the single cell level revealed multiple markers
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that could potentially be modified to maintain the suppressive capacity of the in vitro
expanded B cells for future cell therapy application.
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1. Introduction

1.1 B cell development
B cells are part of the adaptive immune system. They develop in the bone marrow from
hematopoietic stem cells (HSCs). HSCs develop into multipotent progenitors that further
commit into cells of either the myeloid or lymphoid lineage. The common lymphoid
progenitor cells have the ability to differentiate into B cells, T cells or natural killer cells.
Once a cell has committed to the B cell lineage by expressing the transcription factor
E2A, its development is characterized by the status of immunoglobulin heavy and light
chain gene rearrangements that make up its B cell receptor (BCR) (Figure 1). BCRs are
membrane-bound antibodies that are responsible for the antigen specificity of B cells. The
process of creating a unique BCR requires recombining segments of the immunoglobulin
heavy and light chains in a particular order, also known as VDJ recombination. This
portion of B cell development gives rise to a virtually endless possibility of gene
combinations that can be used to form BCRs. While each B cell generates a BCR that
can only recognize a single antigen, the population of B cells as a whole is able to
recognize a wide repertoire of antigens. This diversity in BCRs contribute to the adaptive
immune response (Dorshkind 2018, Proverb 2014, Murphy 2017).
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Figure 1. B cell development. The stages of B cell development are characterized
based on the status of the B cell receptor (BCR) gene rearrangement, which is controlled
by expression of recombination-activating genes RAG1 and RAG2. B cells with
autoreactive or nonfunctional BCRs will undergo receptor editing, anergy, or apoptosis,
while B cells with a functional BCRs exit the bone marrow as transitional B cells.
Reproduced with permission from D. Nemazee, “Mechanisms of central tolerance for B
cells,” (2017). License number: 1081954-1
B cells must pass multiple checkpoints (positive and negative selection) to ensure only B
cells with functional immunoglobulins that do not react to self-antigens will survive and
contribute to an immune response. Positive selection is responsible for ensuring that the
newly generated B cells can recognize antigens through their newly formed BCRs. If the
heavy and light chains are rearranged properly during the developmental process, the
newly formed B cell receptor will provide signaling through the CD79AB immunoreceptor
tyrosine-based activation motif (ITAM), which promotes B cell survival. If the B cell
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receptor does not create a signal, it will undergo receptor editing. If receptor editing fails
to produce a signal, the unresponsive B cell will undergo apoptosis. This process prevents
non-responsive B cells from surviving and entering the periphery. While it is important for
B cells to respond to antigens, it is also important that they do not respond to selfantigens. Negative selection occurs when B cells with a strong affinity for self-antigens
are prevented from contributing to an immune response by undergoing receptor editing,
anergy, apoptosis or clonal deletion. This process allows the establishment of selftolerance which is necessary for preventing autoimmune disorders (Murphy 2017).

1.3 Signals driving B cell response to antigens

Figure 2. Activation of naïve B cells by T cell-dependent or T cell-independent
antigens. B cells can be activated by T cells when antigens that produce weak BCR
signaling along with T cell receptor (TCR) recognition of the same antigen is presented
by major histocompatibility complex II (MHC II) in B cells and CD40 stimulation by CD40
ligand (CD154) expression on T cells. Alternatively, B cells can be activated
independently from T cell help when an antigen crosslinks BCRs, resulting in a strong
BCR signal as well as toll-like receptor (TLR) activation by commonly recognized
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pathogen structures such as lipopolysaccharide (LPS). Reproduced with permission from
K. Murphy, “Janeway’s Immunogbiology” (2017). PLSclear reference number: 44915
The BCR aids B cell activation by producing a signaling cascade when bound to an
antigen. BCRs can also deliver the antigen to intracellular sites so it can be processed
and presented to T cells through MHC class II. As a result, B cell activation involves
signals provided by a T cell through T-dependent activation, or a nonprotein antigen
through T-independent activation (Murphy 2017, Oleinika 2019).

T-cell dependent activation involves two signals. The first signal comes from the BCR
which is enhanced by signaling cascades through CD19 and CD21 (Figure 2). The
second set of signals are provided by T follicular helper cells. These signals include the
TCR binding to MHC II on the B cell, as well as CD40 ligand (CD154) binding to CD40 on
the B cell. Because protein antigens alone are not able to induce a B cell response, Tcell dependent activation allows B cells to become activated by protein antigens.

Similarly, T-independent activation also requires two signals. The first signal comes from
crosslinking of the BCR by a multivalent antigen and the second signal comes from
stimulation of Toll Like Receptors (TLR) by antigens expressing pathogen associated
microbial patterns (PAMPs) such as GpG (TLR9 agonist) or lipopolysaccharide (LPS).
This type of activation allows B cells to rapidly respond to antigens without the help of T
cells (Figure 2, Murphy 2017, Proverb 2014).
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1.3 Maturation of B cell subsets

Figure 3. Differentiation of B-2 cells into various subsets. Once immature B cells exit
the bone marrow, they enter the periphery and travel to secondary lymph organs as
transitional B cells. In the secondary organs, they differentiate into follicular or marginal
zone B cells depending on their BCR specificity. Upon exposure to antigen, marginal zone
B cells will differentiate into short-lived plasma cells while follicular B cells undergo
germinal center reaction and differentiate into memory B or plasma cells. Reproduced
with permission from K. Pieper, “B-cell biology and development,” (2013). License
number: 1081970-1
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As B cells mature and differentiate, they give rise to a number of functionally distinct
subsets shown in Figure 3. The early stages of B cell maturation occur in the bone
marrow, where they are initially produced, and then travel to the spleen where the final
stages of maturation take place. B-1 B cells are a unique subset of B cells since they are
formed in the fetal liver and are responsible for producing protective antibodies that are
not in response to an encounter with a pathogen. On the other hand, B cells derived from
the bone marrow are classified as B-2 cells. When B cells exit the bone marrow, they
enter the periphery as transitional B cells, which are considered T1 cells when they travel
to and enter the secondary lymphoid organs such as the spleen. Once T1 B cells enter
the spleen, they differentiate into T2 B cells. B cell maturation is considered complete
when T2 cells differentiate into either follicular or marginal zone B cells depending on the
signals received (Schroeder 2017, Rawlings 2018).

Marginal zone B cells are less abundant than follicular B cells. They are found in the
marginal zone of the spleen and play an important role in the early adaptive immune
response. Marginal zone B cells can be activated by antigens within hours of exposure
and independently of T cells to produce low affinity antibodies. Thus, they contribute to
the early stages of the adaptive immune response. In contrast, follicular B cells circulate
through primary and secondary lymphoid follicles of the spleen and lymph nodes and rely
on T-cell dependent signals for survival. Because they require signals from T cells to be
activated, it can take days to weeks for follicular B cells to begin producing antibodies.
However, during this time they are able to undergo somatic hypermutation and class
switch recombination, allowing them to produce a range of high affinity antibody isotypes.
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Follicular B cells contribute to the late adaptive immune response and are primarily
responsible for antibody responses against protein antigens. Both marginal and follicular
B cell subsets rely on B cell activating factor (BAFF) signaling for survival.

MZ B cells can respond to T cell-independent antigens and will primarily protect against
blood borne pathogens. Upon activation, they will turn into plasma cells and secrete IgM
immunoglobulins. FO B cells can respond to T cell-dependent antigens and will form
germinal centers when activated. Here, they will undergo somatic hypermutation and
class switch recombination. This process gives rise to B cells that can produce higher
affinity antibodies of different isotypes. FO B cells also have the opportunity to
differentiate into memory B, plasmablasts, or plasma cells in germinal centers (Pieper
2013)

Plasmablasts are considered immature plasma cells. They are short lived, highly
proliferative cells that are produced as an early response to infection and can rapidly
secrete low affinity antibodies. Plasmablasts can be derived from follicular B cells early in
the germinal center response, or directly from MZ B cells. After activation, plasmablasts
have the opportunity to differentiate into plasma cells. Plasma cells can be found in the
spleen, lymph nodes and bone marrow (Figure 3) and have a delayed response to
infection as they undergo affinity maturation in the germinal center, which allows them to
secrete high affinity antibodies. Plasma cells do not proliferate rapidly but can live for long
periods of time and are responsible for secreting high levels of antibodies.
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Memory B cells are responsible for a heightened response to pathogens encountered a
second time. Memory B cells are formed after a primary immune response to an antigen
and are able to produce a more rapid response to a previously recognized antigen. In the
next section, the function of memory B cells is described in more detail (Murphy 2017).

Regulatory B cells (Bregs) are a B cell subset with immunomodulatory functions. Bregs
can inhibit T cell responses by secreting immunosuppressive cytokines including
interleukin (IL)-10, IL-35 and tumor growth factor-beta (TGF-b) and have been shown to
promote regulatory T cell (Treg) formation (Flores-Borja 2013, Rosser 2015). While recent
studies suggest that Bregs can differentiate from all B cell subsets in response to
inflammatory signals or BCR signaling, additional studies are required to determine if
Bregs arise through development or are induced under certain conditions (Rosser 2015).

8

1.5 B cell function in health

Figure 4. Role of B cells in the immune system. B cells are involved in a wide array
of functions of the immune response including antibody production, inflammation,
antigen presentation, memory formation, and cytokine secretion. Used with permission
from U. Selvaraj, “Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention,
Injury, and Repair”, (2016). License number: 1081973-1
While antibody production has historically been the most valued function of B cells, as
shown in Figure 4, the contribution of B cells to the immune response is now recognized
to include antigen presentation, memory formation, cytokine production, as well as
immunomodulatory functions (Selvaraj 2016). Below I discuss in more details some of the
most important roles of B cells in the immune system:
9

1.6 Antibody production
B cells possess multiple functions that make them a critical component to the immune
system, however they are most widely valued for their ability to produce antibodies. These
antibodies can act as membrane-bound surface receptors known as B cell receptors or
are secreted as proteins that contribute to immunity in different ways. While each B cell
is only able to produce antibodies with a single antigen specificity, the population as a
whole, amounts to a wide antibody repertoire capable of recognizing an extensive number
of antigens. Antibodies bind to antigens on the surface of pathogens and inhibit their
function or tag them for destruction by other components of the immune system such as
macrophages, NK cells and mast cells. The portion of the immune system that responds
to antibodies is dependent on the antibody constant (Fc) region. The process of class
switch recombination allows B cells to produce antibodies with the same variable region
but different constant regions. As a result, a B cell can generate antibodies that recognize
the same antigen while providing different modes of protection that are dependent on the
Fc region. Once an antibody is bound to a soluble or surface antigen with its variable
region, cells can use Fc receptors to bind to the Fc region of the antibody. This interaction
prompts the cell to exert its effector function. For example, macrophages will perform
phagocytosis, natural killer cells will secrete cytotoxic cytokines, and mast cells will
release their granules, all resulting in pathogen destruction and clearance. Antibody Fc
regions can also activate portions of the complement system, also resulting in pathogen
destruction. The ability to secrete different isotypes allows the immune system to tailor its
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response to clear different types of pathogens as effectively and efficiently as possible
(Hoffman 2016).

1.7 Antigen presentation
B cells can also contribute to the adaptive immune response as antigen presenting cells.
When the BCR binds to antigen, not only does it activate the B cell through a signaling
cascade, but the BCR and bound antigen are internalized and the antigen is processed.
This allows peptides derived from the antigen to be presented on MHC class II molecules
expressed on the surface of the B cells. CD4+ T cells that have been activated by the
same antigen can then secrete cytokines needed for B cell memory and germinal center
formation, as well as plasma cell formation (Chalasani 2016, Selvaraj 2016, Murphy
2017).

1.8 Memory formation
Memory formation is another protective role of B cells. Immunological memory allows the
immune system to establish a robust response to subsequent exposure to pathogens.
Memory B cells can be formed from short-lived plasma cells or germinal center reactions
during a primary response to an antigen (Figure 4). Memory B cells express Ig genes
that have undergone isotype class switching and possess somatic mutations, and are
able to persist in the body long-term. As a result, memory B cells are able to produce
higher affinity antibodies more rapidly than the previous response. This allows memory B
cells to contribute to the efficient elimination of familiar pathogens (Allen 2019, Selvaraj
2016, Murphy 2017).
11

1.9 Cytokine secretion and immunomodulation
B cells can also impact the immune response by secreting cytokines. Depending on their
intended role, B cells can secrete either proinflammatory or anti-inflammatory cytokines
(Figure 4). Upon activation, B cells can secrete pro-inflammatory cytokines such as
interferon gamma (IFN-g) and tumor necrosis factor alpha (TNF-a) (Chalasani 2016,
Selvaraj 2016).

A subset of B cells named regulatory B cells (Bregs) can modulate the inflammatory
response through the production of anti-inflammatory cytokines that suppress T cells and
promote tolerance. Breg formation can be driven by signals provided by T cells, cytokines,
and TLR stimulation produced in the microenvironment. These signals can induce Breg
formation by B cell subsets from both B1 and B2 lineages. Previous research shows that
Breg formation from both B1 and B2 lineages can be initiated through CD40 ligation, and
that the cytokine IL-21 can initiate IL-10 production in Bregs (Lykken 2015). Bregs are
able to suppress an inflammatory response and promote tolerance by secreting IL-10, IL35 and TGF-b. Cytokine production by Bregs has been shown to inhibit formation of
pathogenic cells and their inflammatory cytokine production while promoting formation of
suppressive regulatory T cells (Tregs) (Selvaraj 2016).
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1.10 Breg function in disease
Because regulatory B cells play a pivotal role in preventing or reducing immune-mediated
inflammation, their absence or dysfunction can contribute to a wide range of diseases.
Multiple groups have shown that missing or dysfunctional regulatory B cells can contribute
to immune-mediated inflammatory conditions including multiple sclerosis, graft versus
host disease (GvHD), systemic lupus erythematosus and rheumatoid arthritis.

Claudia Mauri and her colleagues from University College London showed that a subset
of CD19+ CD24hi CD38hi B cells from rheumatoid arthritis patients were unable to convert
T cells into regulatory T cells. These B cells were also unable to prevent the formation of
Th17 cells, a subset of proinflammatory T cells thought to contribute to a number of
immune-mediated inflammatory diseases, including rheumatoid arthritis (Flores-Borja
2013).

In the context of systemic lupus erythematosus (SLE), Mauri and colleagues also showed
that crosstalk between plasmacytoid dendric cells and regulatory B cells is compromised
in SLE due to altered STAT activation, leading to their inability to produce sufficient
amounts of IL-10. This decrease in IL-10 production by regulatory B cells is thought to
contribute to the pathogenesis of SLE (Menon 2016).

A study by Luisa Klotz and her team found that treatment with Fingolimod, an FDA
approved drug for in multiple sclerosis (MS) that blocks Sphingosine-1-phosphate (S1P)mediated signaling in lymphocytes, induces an increase in the percentage of regulatory
B cells compared to other B cell subsets. It achieves this by limiting the trafficking of
13

naïve cells from the bone marrow, resulting in a higher number of regulatory B cells in
circulation. This increased proportion of regulatory B cells was significantly correlated with
better clinical outcomes (Grützke 2015).

A study led by Katy Rezvani and her team highlighted how Bregs can establish tolerance
to the donor after hematopoietic stem cell transplant and could potentially be used to
mitigate chronic graft versus host disease (Khoder 2014). Taken together, these studies
provide in depth evidence on how properly functioning regulatory B cells are essential to
prevent a variety of immune-mediated inflammatory diseases.

1.11 Efforts to expand B cells for cell therapy
Regulatory B cells are seen as excellent cell therapy candidates due to their
immunomodulatory capabilities (Mauri 2017). A major roadblock in the development of
regulatory B cell therapy is the lack of expansion protocols that support the large-scale
generation of viable regulatory B cells. Several groups have published methods to
expand B cells for the purpose of studying antigen specific B cell responses to
vaccinations, as well as an alternative production method for generating intravenous
immunoglobulin (IVIG) (Muir 2017, Néron 2012). However, the culture methods used in
these studies may not translate well to the generation of regulatory B cells for adoptive
therapy.

The most widely utilized culture system for B cell expansion applies feeder cells that
express CD154 (CD40 ligand). This allows for the CD154 on the feeder cells to interact
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with CD40 expressed on the surface of B cells, which in turn stimulates B cell proliferation
(Néron 2012). This method allows for large scale expansion of B cells, however, further
studies are needed to determine whether these ex vivo expanded B cells can persist longterm after infusion and in the absence of signals provided by the feeder cells. Establishing
a protocol for the large scale expansion of viable B cells independent of feeder cells will
open the door for B cell therapy to be used in the clinic.

1.12 Working Hypothesis
We hypothesize that using genetic engineering tools we can generate a large number of
B cells with an immunosuppressive phenotype and with the potential to be used for future
cell therapy.

15

2. Methods

2.1 Lymphocyte Isolation and B cell selection
The buffy coats used in this study were obtained from Gulf Coast Regional Blood Center,
Houston, TX. The lymphocytes were isolated from peripheral blood mononuclear cells
(PBMCs) from healthy donors using ficoll density-gradient separation. First, the buffy coat
was diluted with phosphate-buffered saline (PBS) in a 1:1 ratio and transferred to a 50 ml
falcon tube containing 15 ml of lymphoprep. The buffy coat was centrifuged at 400 g for
30 minutes, with an acceleration of 5 and a deceleration of 0. After centrifugation, the top
layer containing plasma was aspirated and the white middle layer, containing
lymphocytes, was removed and kept using a 5 ml pipette. The bottom layer containing
erythrocytes and granulocytes was discarded. The lymphocytes were washed once with
50 ml of PBS at 400 g for 10 minutes. The lymphocytes were then washed 3 times with
20 ml PBS for 5 minutes at 400 g, or until a majority of the platelets were removed from
the sample.

B cells were negatively selected from lymphocytes using magnetic beads and following
the Miltenyi Biotec B cell isolation kit protocol. Briefly, B cells were incubated with the
clinimacs buffer (40 µl/107 B cells) and the Miltenyi Biotech antibody cocktail (10 µl/ 107
cells) for 5 minutes at 4oC. The clinimacs buffer (30 µl/107 cells) and Miltenyi Biotech
microbeads (20 µl/ml) were then added to the mixture for 10 minutes at 4oC. The B cells
were selected using the clinimacs magnetic column and the separation filter. Following
isolation, the B cell purity was confirmed by staining for CD19 using flow cytometry. If
the purity was not above 95%, the selection process was repeated.
16

2.2 B cell stimulation
The purified B cells were resuspended in complete stem cell growth medium (SCGM)
(CellGenix) with 10% fetal bovine serum (FBS), 1% Penicillin/streptomycin, and 1% LGlutamine at 0.5 x 106 cells/ml. CpG ODN 2006 (3 µg/ml, Hycuit Biotech). Anti-IgM+IgG
(10 µg/ml, Jackson Immunoresearch) were added to the cell suspension, and 2 X 106
cells/well were plated in a twelve well plate and incubated at 37oC for 48 hours.

2.3 Transduction of activated B cells
Forty-eight hours after stimulation with CpG and anti-BCR (anti-IgM+IgG), B cells were
transduced with an MMLV retroviral construct encoding for CD40 ligand (CD154) with or
without IL-21. Retronectin (Takara Bio) was diluted in PBS at a 1:100 ratio and 1 ml of
diluted retronectin was added to each well in a 24 well non-tissue culture plate and
incubated at 37o C for 4-6 hours. The retronectin was then removed from the culture plate
and the wells were washed with 1 ml of SCGM (10% FBS, 1% penicillin/streptomycin, 1%
L-Glutamine) for 10 minutes at 37oC. The SCGM was then removed and 1 ml of the
retroviral supernatant was added to each well. The plate was then centrifuged at 2000 g
at 32oC for 2 hours. Following centrifugation, the retroviral supernatant was removed and
replaced with 1 ml of fresh retroviral supernatant, as well as 0.5 x106 B cells per well. The
plate was then centrifuged at 2000 g at 32oC for 30 minutes and transferred to the CO2
incubator (37oC) for 24 hours. The next day, 1 ml of SCGM was added to each well. The
transduction efficiency was determined 2-3 days later by flow cytometry analysis.
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2.4 B cell transduction efficiency
To assess the transduction efficiency, 200 µl of cell suspension was placed in a FACS
tube and washed with FACS wash buffer (1% FBS in PBS) at 2000 RPM for 5 minutes.
The supernatant was aspirated and the antibody cocktail (CD19 PECy7, CD40L BV711,
LD AF647) (All from BD Biosciences) was added to each tube. The tubes were incubated
at room temperature in the dark for 20 minutes and washed with FACS buffer at 2000
RPM for 5 minutes. IL-21 production was assessed by intracellular staining. Briefly, after
surface staining, cells were permeabilized by adding 0.5 ml BD permeabilization buffer to
each tube for 40 minutes at 4oC, followed by two wash steps with 2 ml of 1x BD
permeabilization buffer. The IL-21 antibody (30 ng/µl, R&D) was added to each tube and
the cells were incubated at 4oC for 35 minutes. The tubes were then washed with 2 ml of
1x BD permeabilization buffer at 2000 RPM for 5 minutes. The expression of CD19,
CD40L and IL-21 was then assessed using the flow cytometer (BD Fortessa).

2.5 Assessment of B cell proliferation
B cell count and viability were recorded every two days using trypan blue and a cell
cytometer. Cells were mixed with an equal volume of trypan blue and loaded onto a cell
counting slide. The percentage (%) of cell viability was determined by counting the
number of live and dead cells in the sample using a cytometer.
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2.6 Production of CD40L and CD40L-IL21 in the retroviral supernatant
(Transfection)
In order to generate the virus for B cell transduction, murine leukemia virus (MMLV)
retroviral plasmids encoding CD40L or CD40L-IL21 (Figure 5) were cotransfected with
plasmids containing packaging and envelope genes.

A.

B.

LTR hCD40L T2A IL21 LTR

LTR hCD40L LTR

Figure 5. MMLV retroviral construct maps A. MMLV retroviral construct containing
hCD40L and IL-21 genes. B. MMLV retroviral construct containing hCD40L.
One million HEK 293T cells were plated in a petri dish with 12 ml of Dulbecco’s Modified
Eagle Medium (DMEM). The transfection was performed 24 hours later, or when the HEK
293T cells reached at least 70% confluency. First, the media from the confluent plates
were aspirated and fresh, room temperature DMEM was added and incubated at 37oC.
Two thousand nanograms of helper 1 (contains gag and pol proteins), four thousand
nanograms of helper 2 (contains envelope proteins), 37µl of FuGENE and 1 ml of
optimum per reaction were added to a 50 ml falcon tube. One mL of this mixture was
placed into an Eppendorf tube containing 6000ng of the DNA of interest (CD40L or
CD40L-2A-IL21 plasmids), and incubated at room temperature for 15 minutes. The
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mixture was then added dropwise to the plate. The HEK293 T-cells were incubated at 37
o

C for 24 hours. After 24 hours, the supernatant was aspirated and 12 ml of SCGM was

added to each plate. The supernatant was collected 48 and 72 hours post-transfection
and stored at - 80oC for future use.

2.7 Assessing Transfection efficiency of HEK 293T cells
The transfection efficiency was assessed 72 hours after transfection using flow cytometry.
First, 200,000 HEK 293 T cells were collected from the plate and washed with FACS
buffer at 2000 RPM for 5 minutes. The buffer was aspirated, and the cells were incubated
with live dead AF647 (Lifetech) and CD40L BV421 (Biolegend) antibodies for 20 minutes
in the dark at room temperature followed by washings with FACS buffer. The transfection
efficiency was then assessed by determining CD40L expression using a BD Fortessa flow
cytometer.

2.8 Isolation of T cells from peripheral blood mononuclear cells
T cells were isolated using a magnetic negative selection kit (Miltenyi Biotech) following
the manufacturer’s protocol. Briefly, lymphocytes from healthy donor PBMC were
incubated with clinemacs buffer (40 µl/107cells) and the antibody cocktail (10 µl /107 cells)
at 4oC for 5 minutes. The clinimacs buffer (30 µl /107 cells) and magnetic microbeads
(10 µl /107 cells) were then added to the mixture and incubated at 4oC for 10 minutes.
The magnetic columns and separation filters were prewashed with 3 ml of clinimacs
buffer, then the cell mixture was added. The columns were then washed three times with
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clinimacs buffer. The T-cell purity was assessed by determining the surface expression
of CD3, CD4 and CD8 by flow cytometry. If the T cells had a purity of less than 95%, the
selection process was repeated.

2.9 B cell proliferation assay
Magnetically selected carboxyfluorescein succinimidyl ester (CFSE)-labeled (2µl/ml;
ThermoFisher) T cells (106 cells/mL) were resuspended in PBS and incubated at 37o C
for 15 minutes. SCGM and FBS were added to the suspension in a 1:1 ratio. The cells
were centrifuged for 10 minutes at 1200 RPM, then washed twice with 5 ml of complete
SCGM. CFSE staining was determined by flow cytometry under the FITC channel.

2.10 B cell suppression of T cell cytokine production
CFSE-labeled T cells were activated with anti CD3/CD28 microbeads (25 µl l/106 cells)
and immediately co-cultured with B cells at a ratio of 1:1, 1:2, and 1:5 in a 96 well flat
bottom plate for 48 hours. Brefeldin A (BFA) (10 µg/ml), phorbol myristate acetate (PMA)
(50ng/ml) and ionomycin (500ng/ml) (all from Sigma-Aldrich) were added 5 hours prior to
intracellular staining. After 5 hours, cells from each condition were collected and stained
for the following surface markers: CD4, CD8, CD3, and CD19. The cells were then stained
to assess intracellular cytokine production of TNF-a, IFN-g and IL-2.
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2.11 B cell suppression of T cell cytokine proliferation
First, CFSE-labeled T cells were activated with anti CD3/CD28 microbeads (25 µl /10^6
cells) and were immediately co cultured with B cells at a ratio of 1:1, 1:2, and 1:5 on a 96
well flat bottom plate for 72 hours. After 72 hours, the cells were collected and stained for
expression of CD4, CD8, CD3, and CD19 using monoclonal antibodies.

2.12 Immunoglobulin secretion by B cells
Immunoglobulin secretion by B cells was measured by enzyme-linked immunosorbent
assay (ELISA) for IgM, IgG, IgE and IgA following the manufacturer’s protocol
(Invitrogen).

2.13 CD40L-2A-IL21 plasmid transformation
The CD40L-2A-IL21 plasmid construct was made by Addgene. The plasmid was used to
transform NEB 5 a bacteria following the high competent transformation protocol. One
hundred nanograms (100ng) of plasmid DNA was added to 50 µl of NEB5a bacteria. The
bacteria were incubated on ice for 15 minutes, then heat shocked in a 42o C water bath
for 45 seconds. The bacteria were placed back on ice for 5 minutes, then transferred to
a tube containing 950 µl of SOC broth. The bacteria were then placed in a 37o C incubator
and shaken at 150 RPM for one hour. After the one-hour incubation, 4 ml of LB broth was
added to the bacteria along with ampicillin at a concentration of 100mg/ml. The bacteria
were placed in the incubator at 37o C on a shaker at 150 RPM for 6 hours. After 6 hours,
the bacteria were transferred to a flask containing 500 ml LB Broth with ampicillin
(100mg/ml) and incubated at 37o C on a shaker at 150 RPM overnight. The next day, the
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bacteria were centrifuged, and the pellet was stored in -80oC for maxiprep preparation
(plasmid isolation).

2.14 CD40L-2A-IL21 plasmid cloning
A maxiprep selection kit (ThermoFisher) was used to extract the plasmid DNA from the
bacterial pellet formed during the plasmid transformation procedure following
manufacturer’s directions. The DNA concentration was quantified by nanodrop
(ThermoFisher) and stored at -20oC for further use.

2.16 B cell culture
B cells (0.5 x 106 cells/ml) were cultured in complete SCGM media supplemented with
10% FBS, 1% penicillin/streptomycin, 1% L-Glutamine, along with different combinations
of the following cytokines: IL-2 (50 IU/ml), IL-4 (4 ng/ml), and IL-21 (30 ng/ µl).
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2.17 Flow cytometry
Table 1. List of antibodies used for surface staining in functional and proliferation
assays
Antibody

Florophore

Volume per
test

Company

LD

BV 405

0.5 µl

Lifetech

CD19

PE Cy7

1 µl

BD Biosciences

CD4

APC

2 µl

E Biosciences

CD8

PerCP Cy5.5

2 µl

Biolegend

CD3

APC Cy7

1 µl

Biolegend

Two hundred thousand (200,000) B cells were collected, transferred into a FACS tube in
2ml of FACS buffer (1% FBS in PBS) and centrifuged at 2000 rpm at 19 oC for 5 minutes.
After centrifugation, the buffer was aspirated from the tubes and the antibodies shown in
Table 1 were added to each tube for 20 minutes in the dark at room temperature. Cells
were then washed and fixed in 1.8% paraformaldehyde. The tubes were then stored in
the dark at 4oC until acquired on the Fortessa flow cytometer.

Table 2. List of antibodies used for intracellular staining
Antibody

Florophore

Volume per
test

IL-2

PE

2.5 µl

BD Biosciences

TNF-a

AF700

2.5 µl

Biolegend

IFN-g

V450

2.5 µl

BD Biosciences

Company

Immediately after surface staining, 0.5 ml of BD cytofix/cytoperm was added to each
sample at 4o C for 40 minutes. During the incubation period, 1x wash buffer was prepared
by diluting the 10x BD wash buffer with deionized water. When the incubation period was
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over, 1 ml of wash buffer was added to each sample and the cells were centrifuged at
2000 rpm for 5 minutes. The wash buffer was then aspirated and 2 ml of 1x wash buffer
was added to each sample. The samples were centrifuged at 2000 RPM for 5 minutes,
the supernatant was aspirated and an antibody master mix containing the antibodies in
Table 2 was added to each sample. The cells were incubated at 40C for 30 minutes,
Cells were then washed and fixed in 1.8% paraformaldehyde. The tubes were then stored
in the dark at 4oC until acquired on the Fortessa flow cytometer.
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2.18 Mass Cytometry
Table 3. List of antibodies used for mass cytometry
Metal tag

Antibody

Metal tag

Antibody

89Y

CD45

161Dy

BAFF

141Pr

CD138

162Dy

CD79b

142Nd

CD19

163Dy

CD1d

143Nd

CD5

164Dy

CD23

144Nd

HLA ABC

165Ho

CD40

145Nd

CD45RB

166Er

CD24

146Nd

IgD

167Er

CD38

147Sm

CD20

168Er

CD21

148Nd

PDL-1

169Tm

CD45RA

149Sm

CD25

170Er

HLA-DR

150Nd

CD73

171Yb

CD9

151Eu

IGM

172Yb

PDL-2

152Sm

CD95

173Yb

CXCR4

153Eu

CXCR5

174Yb

PD1

154Sm

CD86

175Lu

CD85j

155Gd

CD27

176Yb

CD22

156Gd

CXCR3

209Bi

CD11b

158Gd

CD10

In115

CD80

159Tb

CD11c

Pt194

CD3

160Gd

CD39

Pt198

LD

Sample preparation and acquisition
A protocol developed by the Rezvani lab was used for this project (Li 2019). Briefly, frozen
B cell samples were thawed and stained with cisplatin for two minutes. The samples were
then stained with the antibody panel shown in Table 3 and shaken at 145 RPM for one
hour. Iridium was diluted in 1.8% PFA at a ratio of 1:1000 and added to each sample. The
samples were incubated for 20 minutes in the dark at room temperature. Following
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incubation, the samples were filtered and stored at 4oC until they were acquired using a
Helios instrument (fluidigm) with the Helios 6.5.358 acquisition software (fluidigm) at 300
events/second.

Data analysis
Using Fluidigm normalization software 2, the mass cytometry data were normalized
based on EQTM four element signal shift over time. Cytobank was used to perform ViSNE analysis.
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3. Results

To develop a protocol for B cell expansion, we first stimulated peripheral blood (PB) B
cells with CpG ODN 2006 (3 µg/ml), and anti-IgM+IgG (10 µg/ml) and cytokines IL-2 (50
IU/ml), IL-4 (4ng/ml) and/or IL-21 (30 ng/ml) for 48 hours prior to genetically engineering
these cells with retroviral constructs expressing either CD40L or CD40L and IL-21
(CD40L-2A-IL21) (Figure 6A). B cells transduced with CD40L-2A-IL21 B cells secrete IL21 autonomously and expand to the same extent as B cells expressing CD40L alone
supplemented with exogenous IL-21 (Figure 6B-E). We also tested the effects of IL-2
and IL-4 supplementation on B cell proliferation since they have been previously shown
to be involved in Breg skewing (Lund 2008). We found that a combination of IL-2 and IL4 supplementation significantly increased B cell proliferation when compared to the
supplementation of IL-2 or IL-4 separately. (Figure 6B-E). Taken together, our data
suggest that the combination of CD40L and IL-21 successfully drive B cell proliferation in
vitro and that the addition of IL-2 and IL-4 further increases this fold expansion.
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Figure 6. B cells transduced with CD40L or CD40L-IL21 and supplemented with
cytokines undergo rapid expansion. A. Schematic diagram for the expansion
conditions tested. B. Expansion rate (cell count) of B cells transduced with CD40L and
supplemented with exogenous IL-2 and/or IL-4. C. Expansion rate (cell count) of B cells
transduced with CD40L-2A-IL-21 and supplemented with exogenous IL-2 and/or IL-4. D.
Expansion rate (fold change) of B cells transduced with CD40L and supplemented with
exogenous IL-2 and/or IL-4. E. Expansion rate (fold change) of B cells transduced with
CD40L-2A-IL-21 and supplemented with exogenous IL-2 and/or IL-4.
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Next, we determined if B cells generated using the expansion methods described in
Figure 6 can suppress T cell function. To answer this question, CD40L-2A-IL21expressing B cells were cocultured with activated T cells in the presence of IL-2, IL-4 or
IL-2/IL4 for 48 hours followed by assessment of T cell cytokine production. Resting T cells
that were not activated with CD3/CD28 microbeads served as a negative control. Indeed,
we observed a significant decrease in IFN-g and TNF-a production by activated T cells
when cocultured with B cells (Figure 7A-C). Importantly, this suppressive capacity was
not dependent on IL-2, IL-4 or combined IL-2/IL-4 supplementation (Figure 7A-C). These
findings indicate that B cells transduced with the CD40L-2A-IL21 construct can suppress
T cell function independently from IL-2 or IL-4 cytokines.
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Figure 7. T cell cytokine production is reduced when co-cultured with B cells
expanded in conditions supplemented with IL-2, IL-4, or IL-2/IL4. B Cells were
expanded by CpG/Anti-BCR stimulation for 48 hours, followed by transduction with
CD40L-IL21. Following transduction, the B cells were cultured in complete SCGM media
and supplemented with IL-2 alone, IL-4 alone, or IL-2 and IL-4 combined A. IFN-g and
TNF-a production by T cells cocultured with B cells transduced with CD40L-2A-IL21
construct and supplemented with IL-2. B. IFN-g and TNF-a production by T cells
cocultured with B cells transduced with CD40L-2A-IL21 construct and supplemented with
IL-4. C. IFN-g and TNF-a production by T cells cocultured with B cells transduced with
CD40L-2A-IL21 construct and supplemented with IL-2 and IL-4. Resting T cells were not
activated with CD3/CD28 microbeads and were used as negative control. Activated T
cells were activated with CD3/CD28 microbeads and were used as positive control.
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To examine whether B cells expressing CD40L or CD40L-2A-IL21 could suppress T cell
proliferation, we labeled T cells with CFSE, activated them with CD3/CD28 beads and
cultured them with or without Bregs for 72 hours. Non-activated (resting) T-cells were
used as negative control. As shown in Figure 8A-C, B cells cocultured with activated T
cells significantly reduced T cell proliferation compared to activated T cells cultured alone.
The addition of IL-2 or IL-4 did not increase the suppressive activity of B cells further.
These findings support an immunomodulatory effect for B cells stably expressing CD40L
or CD40L-21.
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Figure 8. CD40L-IL21 transduced B cells expanded in conditions supplemented
with IL-2, IL-4, or IL-2 and IL-4 suppress T-cell function. B Cells were expanded by
CpG/Anti-BCR stimulation for 48 hours, followed by transduction with CD40L-IL21.
Following transduction, the B cells were cultured in complete SCGM media and
supplemented with IL-2 alone, IL-4 alone, or IL-2 and IL-4 combined. A. Percent
proliferation of T cells when cocultured with CD40L-IL21 transduced B cells expanded
with IL-2. B. Percent proliferation of T cells when cocultured with CD40L-IL21 transduced
B cells that were expanded with IL-4. C. Percent proliferation of T cells when cocultured
with CD40L-IL21 transduced that were expanded with the combination of IL-2 and IL-4.
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Next, we examined whether the suppression of T cells by B cells is dependent on the B:T
cell ratios (1:1, 1:2, 1:5) or the length of culture (up to 10 days) . The addition of B cells
to activated T cells at a 1:1 ratio resulted in a significant decrease in IFN-g, TNF-a and
IL-2 production (Figure 9A-C). However, B cells were unable to suppress T cell cytokine
production at B:T cell ratios of 1:2 or 1:5 (Figure 9A-C). We also observed that the B cell
suppressive capacity was transient and was lost over time Figure 9A-C).

B cell suppression of T cell cytokine secretion
is dose dependent and is lost over time

Figure 9
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Figure 9. CD40L-IL21 transduced B cells expanded in conditions supplemented
with IL-2 and IL-4 suppress T-cell cytokine production. B cells were expanded by
activation with CpG and Anti-BCR, followed by transduction with CD40L-IL21 and
cultured in SCGM with IL-2 and IL-4. A. TNF-a production by T cells cultured with B
cells at different ratios over time. B. IFN-g production by T cells cultured with B cells at
different ratios over time. C. IL-2 production by T cells cultured with B cells at different
ratios over time.

We next investigated if the B:T cell ratio or length of culture also affected T cell
proliferation. As shown in Figure 10, we cocultured B cells with CFSE-labeled T cells at
B:T cell ratios of 1:1, 1:2 and 1:5 and observed that B cells are only able to suppress T
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cell proliferation when cocultured at a 1:1 ratio. However, B cells were unable to suppress
T cell proliferation at B:T cell ratios of 1:2 or 1:5. Moreover, B cells lost their ability to
suppress T cell proliferation as they over time in culture (Day 5 vs Day 9) indicating that
B cells are capable of suppressing T cell proliferation, an effect that is diminished over
time.

B cell suppression of T cell proliferation is
dose dependent and is lost over time

Figure 10
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Figure 10. CD40L-IL21 transduced B cells expanded in conditions supplemented
with IL-2 and IL-4 suppress T-cell proliferation. B cells were expanded by activation
with CpG and Anti-BCR, followed by transduction with CD40L-IL21 and cultured in
SCGM with IL-2 and IL-4. A-C Percentage of proliferation of CFSE labeled T cells that
were cultured with B cells at different ratios at day 5 (A), day 7 (B) and day 9 (C) after B
cell transduction. Resting T cells (dark blue) were not activated with CD3/CD28
microbeads and were used as the negative control. T cells (red) activated with CD3/CD38
microbeads were used as positive control.
To gain a deeper understanding of the changes in the phenotype pf B cells upon
activation, we used cytometry by time-of-flight (CytoF) and a panel of 40 antibodies
against markers of B cell activation, survival, homing and differentiation (Table 3). Using
viSNE, a t-distributed stochastic neighbor embedding (tSNE) algorithm, we next analyzed
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and displayed high-dimensional data on two-dimensional maps (Figure 11). Activation of
Nontransduced B cells with CpG and anti-IgM for 48 hours resulted in downregulation of
CD1d and CD24, CD79b, and IgD (Figure 11 B). CD1d is a surface molecule found on
B cells that can present nonpeptide antigens to invariant natural killer T (iNKT) cells and
has previously been shown to be downregulated in highly proliferative B cells (Chaudhry
2014). Activation of the surface molecules CD24 and IgD has been previously shown to
promote B cell apoptosis (Suzuki 2001 and Yang 2018). Therefore, downregulation of
these markers may decrease the likelihood of B cells undergoing apoptosis. CD79b is
involved in mediating BCR signaling, and it is unclear as to why it would be downregulated
upon BCR activation. However, it could be a negative feedback mechanism described by
Grundström and colleagues, which argue that this downregulation can aid in higher BCR
affinity (Verma-Gaur 2012). We also found that following activation with CpG and antiIgM for 48 hours, B cells upregulated CD39, CD85j, CD86, CD25 and PD-L1 (Figure
11B). CD39 is an ectoenzyme involved in 5-Amp mediated signaling and has been
previously associated with Breg function and phenotype (Figueiro 2016). This suggests
that upregulation of CD39 may indicate an increase in B cell immunomodulatory function.
In addition, CD85j is an inhibitory molecule that has been shown to regulate antibody
production (Merlo 2005). An increase in CD85j expression may influence the isotype and
number of antibodies produced by these cells, however more studies are needed to
confirm this phenomenon. CD86 is a costimulatory molecule expressed by B cells and
promotes B cell proliferation (Suvas 2002). Upregulation of CD86 contributes to the
proliferative state of activated B cells. Both CD25 and PD-L1 have previously been shown
to play a role in Breg formation, indicating that activation with CpG and anti-IgM may lead
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to a higher percentage of regulatory B cells when compared to activation by CD40L and
IL-2. This experiment highlights the heterogeneity of B cell populations found in PBMCs
and the influence of B cell activation in driving an immunoregulatory phenotype.
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B cells gain CD25 and PD-L1 expression
following activation with CpG/Anti-BCR

Figure 11

A
CD40L Naive
CD40L Unswitched
CD40L Switched
Resting Switched Memory
Resting Unswitched Memory
Resting Naive
CpG/Anti-BCR Activated

B

39

Figure 11. B cells gain CD25 and PD-L1 expression following activation with
CpG/Anti-BCR B cells were isolated from PBMCs and activated with either CD40L
or Cpg/anti-BCR for 48 hours. A. Displays the location of each B cell subset on the tSNE map. B. Represents Individual t-SNE maps displaying the surface expression of 39
different B cell markers.

Since expanded B cells lose their capacity to suppress T cell cytotoxicity and proliferation
in culture over time, we next examined changes in their surface expression at different
culture timepoints by mass cytometry (Figure 12). We compared the phenotype of B cells
at a timepoint when they are known to be suppressive (day 7) and once they have lost
their suppressive abilities (day 21) (Figure 12 A). We then performed a t-SNE analysis in
order to demonstrate the differences in surface marker expression between the two
timepoints. This analysis allowed us to visualize high-parameter data on the single cell
level. We most notably found that while CD73, PD-L1 and CD25 are expressed on day 7
of culture when the B cells are suppressive, the expression of these markers is lost after
21 days of culture (Figure 12 B). These data suggest that CD73, PD-L1 and CD25 may
play an important role in the suppressive capacity of our B cells and their loss overtime
may contribute to the transient suppressive capacity of B cells generated with this
protocol.
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Figure 12. CD40L-IL21 transduced B cells expanded in conditions supplemented
with IL-2 and IL-4 lose CD25 and PD-L1 expression after 3 weeks of culture. B cells
were activated with CpG and Anti-BCR for two days, followed by transduction with
CD40L-IL21. Following transduction, the B cells were cultured in complete SCGM media
and supplemented with IL-2 and IL-4. A t-SNE map displaying B cell populations in culture
for 7 days (orange) or 21 days (blue). B. t-SNE maps displaying the expression intensity
of 39 surface markers. Low expression levels are represented by the color blue while high
expression levels are represented by the color red.

4. Discussion

The immunomodulatory functions of B cells make them attractive candidates for cell
therapy of inflammatory immune diseases. However, a reliable method for the large-scale
expansion of B cells with suppressive capabilities has not yet been developed. We
hypothesized that using genetic engineering tools we can generate a large number of B
cells with an immunosuppressive phenotype and with the potential to be used for future
cell therapy. Here, we demonstrate that B cells can acquire immunoregulatory function
following activation transduction with CD40L, or CD40L and IL-21. Moreover, we provided
evidence of T cell suppression by B cells through functional assays assessing T cell
cytotoxicity and proliferation. We found that our B cells are capable of effectively
suppressing T cell cytotoxicity and proliferation but that this effect was transient. In order
to gain a deeper understanding of why expanded B cells only transiently suppress T-cell
activity, we performed CytoF to interrogate the phenotype of the cells at the single cell
level. We found that upon activation, B cells gain CD25 and PDL-1 expression. However,
after 3 weeks of culture, the expression of CD73, CD25 and PDL-1 is lost. These data
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suggest that these molecules play an important role in the underlying mechanism through
which regulatory B cells gain their immunosuppressive function.

Figure 13. Signals shown to play a role in Breg formation. Multiple signals can
contribute to Breg formation, including T-cell derived signals, cytokines, and microbial
derived antigens Reproduced with permission from C. Mauri, “Human regulatory B cells
in health and disease: therapeutic potential” (2017). License number: 1081976-1

Since our goal was to create a protocol for large scale B cell expansion, we were
interested in understanding the signals required for B cell proliferation. We chose to first
activate B cells by stimulating them through their BCR and TLR, which has been
previously shown to induce Breg formation (Figure 13). Philippe Musette and colleagues
(Bouaziz 2010) demonstrated that stimulating B cells with CpG and anti-BCR will promote
Breg formation. However, stimulation of B cells through these signals alone failed to
induce large scale expansion of B cells. In an attempt to increase the proliferation of these
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B cells, we genetically engineered them with retroviral constructs containing CD40L, a
marker normally expressed by T cells that has also been shown to induce Breg formation
(Figure 13). Thomas Tedder and colleagues used adoptive B cell transfers in a mouse
model of experimental autoimmune encephalitis (EAE), commonly used to study multiple
sclerosis, to show that CD40 stimulation can aid in Breg formation. Their studies revealed
that B cells that do not express CD40 fail to diminish the severity of EAE when infused
into B cell-deficient mice. However, infusion of B cells expressing CD40 that were cultured
with CD40L and IL-21 expressing feeder cells were able to significantly diminish EAE
disease severity. This study highlights the importance of CD40 signaling in Breg formation
(Lykken 2015).

Our findings confirmed the importance of IL-21 in B cell proliferation, as B cells transduced
with CD40L that were not supplemented with IL-21 in the media had significantly lower
expansion rates (Figure 6). However, B cells transduced with CD40L-2A-IL21, which had
the ability to secrete IL-21, had similar expansion rates of those transduced with CD40L
alone that were supplemented with exogenous IL-21. These data support the notion that
IL-21 drives B cell proliferation.

In order to promote the survival and proliferation of B cells, we tested the addition of
different cytokines to the culture, including IL-2 and IL-4. IL-4 has been previously used
to drive Breg formation (Lykken 2015). In addition, IL-2 has also been shown to promote
B cell proliferation. Our studies showed that IL-2 and IL-4 cytokine supplementation
significantly increased B cell proliferation rates.
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We next asked if the expanded B cells could suppress T cell function in vitro. Previous
research has shown that coculturing CD19+ CD24hi CD38hi B cells with T cells can limit T
cell cytokine production and proliferation (Flores-Borja 2013). While our functional studies
confirmed the immunosuppressive capacity of expanded B cells, this effect was lost when
the B cells were kept in culture over time.

To understand why the expanded B cells lost this suppressive capability overtime, we
used mass cytometry (CyTOF) to interrogate the phenotype of the B cells at the single
cell level. We found that upon activation with CpG and anti-IgG/IgM, B cells express PDL1 and CD25 (Figure 11). We next examined the surface expression of various markers
on the surface of B cells cultured for 7 days (when they were immunosuppressive) versus
21 days (by which time they had lost their immunosuppressive function). We found that
B cells lose expression of PD-L1, CD73 and CD25 by day 21 of culture (Figure 12),
suggesting that these markers may be important the ability of B cells to suppress T cell
cytotoxicity and proliferation.

In summary, we were able to achieve a 300-fold expansion of primary B cells after
retroviral transduction with CD40L and supplementation with cytokines, including IL21
(+/- IL2 and/or IL4) (Figure 6). In addition, we were able to use functional studies to
demonstrate the suppressive capacity of B cells on T cell function and proliferation.
However, the ability of B cells to suppress T-cell function was transient and depended on
the B:T cell ratio. To gain insight into the potential mechanisms that could explain why
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these B cells lose their capacity to suppress T cell proliferation and cytokine secretion,
we performed mass cytometry to phenotypically profile the suppressive B cells over time.
The data generated from these experiments pointed to a number of signaling pathways
that we could potentially manipulate in future studies in an attempt to prolong the B cell
suppressive function.
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5. Future directions

In this study we successfully developed the protocol for the genetic modification and
expansion of primary B cells with immunosuppressive properties. However, these B cells
lost their suppressive capacity over time. Understanding the mechanisms underlying this
loss of suppression will provide us with valuable insight that could help us design future
experiments to expand B cells with long term suppressive capacity.

There are multiple factors that could be contributing to this transient suppression. One
possibility could be their inability to secrete suppressive cytokines over time. In order to
test this, we would like to perform ELISA (enzyme-linked immunosorbent assay) to
measure the levels immunosuppressive cytokines such as IL-10, IL-35, and TGF-b in
supernatants collected from B cells cultured over time. We anticipate a decrease in IL10, IL-35, and/or TGF-b secretion in B cells that lose their suppressive capacity over time.

Another possibility could be alterations in the metabolism of B cells as they are cultured
over time. In the future, we would like to study the metabolic profile of expanded B cells
over time and correlate our findings with their suppressive function. There is compelling
evidence suggesting that activated Tregs have altered lipid metabolic pathways that
contribute to their survival and immunosuppressive functions (Field 2019). Preliminary
data from our lab also suggest that regulatory B cells may work through similar
mechanisms. We plan to perform single cell RNA sequencing to define the metabolic
transcriptomic profile of regulatory B cells as they are kept in culture. In addition, we plan
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to use the Seahorse assay to determine the mitochondrial respiration and glycolytic
capacity of B cells generated under different conditions. These experiments will allow us
to determine how the B cell metabolic profile is changing over time.

We would also like to assess changes in telomere length of B cells as they continue to
divide in culture. Telomere length has been previously identified as a way of protecting
chromosome integrity, and that telomere length can be associated with B cell antibody
responses. Najarro and colleagues demonstrated that B cells that produce a robust
antibody response are associated with longer telomeres, while B cells that produce a
weak antibody response are associated with shorter telomeres (Najarro 2015). However,
elucidating the telomere length in suppressive B cells has not yet been shown. We are
interested in seeing if the telomere length changes as B cells are kept in our culture
conditions, as we may be able to associate shorter telomere length with a loss in
suppressive capacity.

We plan to analyze the clonality of B cells expanded using these culture methods, to
determine if the cells with suppressive function are oligo or polyclonal. This information
will provide insight to the B cell repertoire of the expanded B cells and whether certain
clones could have a greater suppressive capacity.

Lastly, we would like to test the in vivo suppressive activity of induced regulatory B cells
in a xenogeneic NOD SCID gamma mouse model of graft versus host disease (GvHD).
We will use the established xenogeneic mouse model of GVHD in our lab to test the in
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vivo suppressive activity of Bregs. In addition, to determine the optimal cell dose, we will
ascertain the optimal scheduling of Breg administration as well as the dose of B cells
needed to mitigate signs of GVHD. These studies will determine if ex vivo engineered
and activated B cells can suppress T cell inflammation in an in vivo setting.
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